Sponsored message
Logged in as
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
  • Listen Now Playing Listen

This archival content was originally written for and published on KPCC.org. Keep in mind that links and images may no longer work — and references may be outdated.

KPCC Archive

STUDY: UCLA researchers find potential new weapon to battle HIV and other deadly viruses

SAN ANSELMO, CA - NOVEMBER 23:  A pharmacist pours Truvada pills back into the bottle at Jack's Pharmacy on November 23, 2010 in San Anselmo, California.  A study published by the New England Journal of Medicine showed that men who took the daily antiretroviral pill Truvada significantly reduced their risk of contracting HIV. (Photo Illustration by Justin Sullivan/Getty Images)
SAN ANSELMO, CA - NOVEMBER 23: A pharmacist pours Truvada pills back into the bottle at Jack's Pharmacy on November 23, 2010 in San Anselmo, California. A study published by the New England Journal of Medicine showed that men who took the daily antiretroviral pill Truvada significantly reduced their risk of contracting HIV. (Photo Illustration by Justin Sullivan/Getty Images)
(
Justin Sullivan/Getty Images
)

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today.

Listen 0:47
STUDY: UCLA researchers find potential new weapon to battle HIV and other deadly viruses

UCLA researchers say they may be a step closer to battling several deadly viral diseases, including HIV and Ebola. 

In a study published in the current issue of the journal Immunity, researchers identified a protein containing what they say are novel antiviral properties that appear to keep HIV from developing in certain laboratory mice.

The scientists say the  protein cholesterol-25-hydroxylase (CH25H) contains an enzyme that can permeate a cell’s wall and potentially block those deadly viruses from entering it.

For their study, researchers injected the enzyme into mice that were implanted with human tissue and with HIV. Within a week, it reduced the HIV viral load in the mice and reversed the depletion of infection-fighting T-cells caused by HIV, said lead author Su-Yang Liu, a student in the department of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at UCLA.

The scientists say they hope their findings will help in the development of medications that battle HIV and other serious viruses in humans. Read the full study below:

LiuCH25H[1] by

You come to LAist because you want independent reporting and trustworthy local information. Our newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our connected community. We are free to tell the full truth, to hold power to account without fear or favor, and to follow facts wherever they lead. Our only loyalty is to our audiences and our mission: to inform, engage, and strengthen our community.

Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive from readers like you will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.

If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.

Your tax-deductible donation keeps LAist independent and accessible to everyone.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today